Arax Advisory Partners’s BeOne Medicines Ltd ONC Stock Holding History

Arax Advisory Partners’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$34.5K	Buy	121 +112	+1,244%	+$33K	﹤0.01%	3577
2026 Q1	$2.73K	Sell	9 -15	-63%	-$4.86K	﹤0.01%	3015
2025 Q4	$7.39K	Buy	24 +21	+700%	+$6.87K	﹤0.01%	2641
2025 Q3	$1.02K	Sell	3 -5	-63%	-$1.52K	﹤0.01%	3252
2025 Q2	$1.94K	Sell	8 -5	-38%	-$1.23K	﹤0.01%	2576
2025 Q1	$3.54K	Buy	13 +9	+225%	+$2.1K	﹤0.01%	1900
2024 Q4	$739	Hold	4	–	–	﹤0.01%	2241
2024 Q3	$900	Sell	4 -3	-43%	-$540	﹤0.01%	2289
2024 Q2	$1K	Hold	7	–	–	﹤0.01%	2174
2024 Q1	$1.09K	Buy	7 +4	+133%	+$644	﹤0.01%	1140
2023 Q4	$542	Hold	3	–	–	﹤0.01%	1217
2023 Q3	$540	Sell	3 -2	-40%	-$396	﹤0.01%	1233
2023 Q2	$892	Hold	5	–	–	﹤0.01%	1127
2023 Q1	$1.08K	Hold	5	–	–	﹤0.01%	1090
2022 Q4	$1.1K	Hold	5	–	–	﹤0.01%	1052
2022 Q3	$1K	Hold	5	–	–	﹤0.01%	1182
2022 Q2	$1K	Sell	5 -6	-55%	-$937	﹤0.01%	1136
2022 Q1	$2K	Buy	11 +5	+83%	+$1.06K	﹤0.01%	977
2021 Q4	$2K	Buy	+6	New	+$2.03K	﹤0.01%	943

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Arax Advisory Partners's ONC Position: Q2 2026 in Review

Arax Advisory Partners increased its BeOne Medicines Ltd (ONC) stake by 1,244% in Q2 2026, buying an estimated $33K and bringing the position to 121 shares worth $34.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3577.

Arax Advisory Partners first reported a position in ONC in Q4 2021 and has held it in 19 quarters since. 282 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

Arax Advisory Partners held 121 shares of BeOne Medicines Ltd worth $34.5K as of Q2 2026.
Arax Advisory Partners bought 112 BeOne Medicines Ltd shares in Q2 2026, an estimated $33K.
BeOne Medicines Ltd made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3577 holding.
Arax Advisory Partners first reported a position in BeOne Medicines Ltd in Q4 2021 and has held it in 19 quarters since.
282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.